MSLE: SEC Form 6-K filed by Satellos Bioscience Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for MSLE
Across the 20 sessions after earlier MSLE headlines, the stock closed higher 8 times and lower 12 times, with a median move of 4.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MSLE | SPY |
|---|---|---|---|
| Sep 15, 2026 | Satellos to Present at the 31st Annual Congress of the World Muscle Society | -4.4% | -0.5% |
| Sep 9, 2026 | Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 | +9.2% | -0.5% |
| Sep 1, 2026 | Satellos to Participate in Upcoming Investor Conferences | -2.8% | -0.7% |
| Aug 14, 2026 | Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress | -2.1% | -0.2% |
| Jul 8, 2026 | Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 | +9.4% | -0.3% |
| Jun 29, 2026 | Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy | +11.4% | +1.6% |
Quantisnow market dataNASDAQ
MSLE
Satellos Bioscience Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for MSLE
Full MSLE profile on Quantisnow Follow MSLE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time